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b Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USAThe plethora of new publications on non-alcoholic fatty liver dis-
ease (NAFLD) in both pediatric and adult populations worldwide is
testimony to the scale of this problem (Abd El-Kader and El-Den
Ashmawy, 2015; Sanyal et al., 2015). Projections on the numbers of
cases as well as related liver transplantations in the coming decades
underscore the urgent need for expanded research into the mecha-
nisms through which NAFLD develops and the design of more effec-
tive strategies for its management. In this issue of EBioMedicine,
Baratta et al. present data suggesting that a blood test for lysosomal
acid lipase (LAL) activitymight serve as a useful tool for these endeavors
(Baratta et al., 2015).
Baratta and colleagues screened LAL activity in substantial numbers
of NAFLD (n=240) andNASH (n=35) patients, aswell as healthy sub-
jects (n = 100), using a modiﬁed, validated technique that employs
dried blood spots (Hamilton et al., 2012). The data show that NAFLD
patients had signiﬁcantly lower LAL activities than healthy subjects,
and that activities were even lower in NASH patients. This study's ﬁnd-
ings have important implications for the potential use of blood LAL
activity as a screen in the detection and management of NAFLD. Inher-
ent in this premise is the assumption that the activity of LAL detected
in dried blood spots faithfully reﬂects that in cells throughout the
body, particularly in the liver.
LAL plays a key role in the regulation of intracellular lipid homeo-
stasis. Speciﬁcally, it hydrolyzes esteriﬁed cholesterol (EC) and tri-
glycerides (TG) contained within lipoproteins, particularly low
density lipoproteins (LDL) and related particles, that are taken up
by cells via receptor-mediated and bulk-phase endocytosis. Mutations
in LIPA, the gene that encodes LAL, result in either Wolman Disease, or
in Cholesteryl Ester Storage Disease (CESD). Whereas WD is a severe,
early onset illness caused by complete loss of LAL activity, CESD is a
milder, later-onset disease resulting from partial LAL deﬁciency that
is often accompanied by dyslipidemia and a predisposition to atheroscle-
rosis (Scott et al., 2013; Grabowski et al., 2015). Hepatomegaly and a
massive increase in tissue EC content and also in TG levels, especially in
the liver, are hallmark features of both disorders which can be treated
with enzyme replacement therapy (Balwani et al., 2013). One of the
more notable ﬁndings in the present study was that in the 50% of the
NAFLD patients with LAL activities below the median, serum LDL-DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.05.018.
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2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article undercholesterol levels were higher. However, the proportion of subjects
in this group receiving statin therapy (28.0%) was signiﬁcantly lower
than in the other half of patients whose LAL activities were above the
median (43.3%). The implied beneﬁt of statin therapy in NAFLD patients
here raises the question of whether this is also the case in individuals
with CESD. As recently discussed (Reiner et al., 2014), statin therapy
may be detrimental in individuals with CESD. To the extent that statins
increase receptor-mediated clearance of LDL, particularly in the liver, an
accelerated rate of lysosomal EC entrapment could likely increase liver
damage in the face of a reduction in the circulating LDL-cholesterol level.
Perhaps the most fundamental question raised by the data from the
current study centers on the mechanism(s) that causes LAL activity to
fall in NAFLD and NASH patients, and which might explain their appar-
ent favorable response to statins. Answering this requires delineation of
how intrahepatic cholesterol metabolism changes at a biochemical and
molecular level inNAFLDandNASH. Several published studies provide a
fascinating insight into the nature of these changes. Detailed data
for mRNA and protein levels for a constellation of genes involved in reg-
ulating sterol homeostasis in the liver revealed, amongst other changes,
an elevated rate of cholesterol synthesis, depressed LDL-receptor
expression, and reduced levels of activity of several key sterol trans-
porters in NAFLD/NASH patients (Min et al., 2012). These changes par-
allel those known to occur in CESD. However, there is one particular
difference between CESD and NAFLD/NASH patients that warrants
emphasis. In CESD, hepatic EC levels are often elevated more than
100-fold, with accompanying dramatic increases in tissue TG levels
along with, at most, a marginal rise in the concentration of unesteriﬁed
cholesterol (UC). Lipidomic analyses of liver tissue from NAFLD and
NASH patients revealed that the dramatic rise in TG levels was accom-
panied by an elevated UC concentration, particularly in the subjects
with NASH (Puri et al., 2007). Surprisingly, hepatic EC levels in these
patients were not different from those in control subjects. The potential
consequences of the rise in hepatic UC levels depend partly on the sub-
cellular site where this buildup occurs. If increased UC concentrations
lead to down regulation of hepatic LDLR expression, then conceivably
lower rates of LDL-EC and LDL-TG entry into the lysosomal compart-
ment might lead to an adaptive fall in LAL activity.
While further exploration of these mechanisms is essential, so too is
the development of reliable biomarkers for identifying NAFLD/NASH
patients and monitoring their response to treatment. The results of
the current investigationdemonstrate thepotential of blood LAL activity
in meeting this need.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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